Internal Medicine Residency, University of Washington, Seattle, WA, United States.
Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, MA, United States.
Drug Alcohol Depend. 2021 May 1;222:108662. doi: 10.1016/j.drugalcdep.2021.108662. Epub 2021 Mar 18.
Management of chronic pain is an essential aspect of HIV primary care. Previous literature in the general population has elucidated racial disparities in the evaluation and treatment of pain. This study examined racial/ethnic differences in patient satisfaction and barriers to pain management among a cohort of PWH receiving LTOT.
Patient-reported survey and EMR data were compared between non-white (n = 135; 81.3 %) and white (n = 31; 18.7 %) patients in a cohort of 166 PWH receiving LTOT in two clinics in Atlanta and Boston. Quantile and linear regression were used to evaluate the association between race and pain management outcomes: 1) satisfaction with pain management (0-10) and 2) patient-related barriers to pain management, including patient perceptions of pain medications, fatalism, and communication about pain. Models were adjusted for sex, age, clinical site, and baseline general health.
Non-white participants were noted to receive chronic opioids for a shorter mean duration of time than white participants (6.0 versus 11.0 years, p < 0.001) and lower mean morphine equivalent daily dose (MEDD) than white participants (28.1 versus 66.9 mg, p < 0.001). In adjusted analyses, there was no significant difference in satisfaction with pain management among non-white and white participants (p = 0.101). There was no significant difference in barriers to pain management in unadjusted (p = 0.335) nor adjusted models (p = 0.397).
While non-white PWH were noted to have received lower doses of chronic opioids and for shorter duration than white PWH, satisfaction with pain management was similar. Patient-related barriers to pain management were similar among non-white and white PWH.
慢性疼痛的管理是 HIV 初级保健的重要方面。先前在普通人群中的文献阐明了在疼痛评估和治疗方面存在种族差异。本研究检查了接受 LTOT 的 HIV 感染者队列中,非裔/西班牙裔(n = 135;81.3%)和白人(n = 31;18.7%)患者在患者满意度和疼痛管理障碍方面的种族/民族差异。
在亚特兰大和波士顿的两家诊所中,对接受 LTOT 的 166 名 HIV 感染者队列中,非白人(n = 135;81.3%)和白人(n = 31;18.7%)患者的患者报告调查和 EMR 数据进行了比较。使用分位数和线性回归评估了种族与疼痛管理结果之间的关联:1)对疼痛管理的满意度(0-10)和 2)患者对疼痛管理的障碍,包括患者对疼痛药物的看法、宿命论和对疼痛的沟通。模型调整了性别、年龄、临床地点和基线一般健康状况。
与白人参与者相比,非白人参与者接受慢性阿片类药物治疗的平均时间较短(6.0 年与 11.0 年,p < 0.001),平均美沙酮等效日剂量(MEDD)也较低(28.1 毫克与 66.9 毫克,p < 0.001)。在调整后的分析中,非白人参与者与白人参与者的疼痛管理满意度没有显著差异(p = 0.101)。在未经调整(p = 0.335)和调整后的模型中(p = 0.397),疼痛管理障碍没有显著差异。
尽管非白人 HIV 感染者接受的慢性阿片类药物剂量较低且时间较短,但对疼痛管理的满意度相似。非白人 HIV 感染者和白人 HIV 感染者在疼痛管理方面的患者相关障碍相似。